You are here: Home / Our research / Laboratory of Molecular Neuroscience 

Dr Damian Holsinger

Lecturer in Neuroscience
Biomedical Sciences, School of Medical Sciences

M02 - Mallet Street Campus
The University of Sydney
NSW 2006 Australia

T:+61 2 9351 9324 (or 0876)
F:+61 2 9351 9520
E:

Biographical details

Damian Holsinger began investigating molecular mechanisms underlying Alzheimer's disease in 1997. In 2002 he made the seminal discovery that levels of the pivotal AD-related enzyme, BACE1, were increased in the brain of patients. These findings have been widely accepted in the field and have led to a concentrated focus on this enzyme as a therapeutic avenue for the treatment of Alzheimer’s disease. In 2006, Damian accepted a position as Lecturer in Neuroscience at The University of Sydney and founded the Laboratory of Molecular Neuroscience at the Brain & Mind Research Institute in 2007. He continues to investigate molecular mechanisms underlying neurodegenerative diseases with a particular focus on BACE1.

Back to Top

Research interests

Research interests surround the understanding of mechanisms by which complex neurological disorders arise and methods of treating these diseases.

Back to Top

Current national competitive grants*

2009

in vivo regulation of the Alzheimers disease beta-secretase, BACE1
Holsinger D
NHMRC Project Grants ($277,000 over 3 years)

* Grants administered through the University of Sydney

Back to Top

Keywords

Dementia; Cell biology; Molecular biology; Alzheimer's disease; Aging

Back to Top

Publications

2009 | 2008 | 2006 | 2004 | 2003

2009

  
  • Kassiou, M., Banati, R., Holsinger, R., Meikle, S. Challenges in molecular imaging of Parkinson's disease: A brief overview. Brain research bulletin. 2009; 78:105-8. [Abstract]

2008

  
Back to Top
  • Einfeld, S., Götz, J., Holsinger, R. Pathogenetic mechanisms in Down Syndrome. Journal of intellectual disability research. 2008; 52:813. [Abstract]

2006

  
Back to Top
  • Holsinger, R., Lee, J., Boyd, A., Masters, C., Collins, S. CSF BACE1 activity is increased in CJD and Alzheimer disease other dementias. Neurology. 2006; 67:710-712. [Abstract]
  • White, A., Du, T., Laughton, K., Volitakis, I., Sharples, R., Xilinas, M., Hoke, D., Holsinger, R., Evin, G., Cherny, R., Hill, A., Barnham, K., Li, Q., Bush, A., Masters, C. Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. The Journal of biological chemistry. 2006; 281:17670-17680. [Abstract]
  • Beckman, M., Holsinger, R., Small, D. Heparin activates beta-secretase (BACE1) of Alzheimer's disease and increases autocatalysis of the enzyme. Biochemistry. 2006; 45:6703-6714. [Abstract]
  • George, A., Holsinger, R., McLean, C., Tan, S., Scott, H., Cardamone, T., Cappai, R., Masters, C., Li, Q. Decreased phosphatidylethanolamine binding protein expression correlates with Abeta accumulation in the Tg2576 mouse model of Alzheimer's disease. Neurobiology of aging. 2006; 27:614-623. [Abstract]

2004

  
Back to Top
  • George, A., Holsinger, R., McLean, C., Laughton, K., Beyreuther, K., Evin, G., Masters, C., Li, Q. APP intracellular domain is increased and soluble Abeta is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease. Neurobiology of disease. 2004; 16:124-132. [Abstract]
  • Holsinger, R., McLean, C., Collins, S., Masters, C., Evin, G. Increased beta-Secretase activity in cerebrospinal fluid of Alzheimer's disease subjects. Annals of neurology. 2004. p. 898-899. [Abstract]

2003

  
Back to Top
  • Evin, G., Zhu, A., Holsinger, R., Masters, C., Li, Q. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets. Journal of neuroscience research. 2003; 74:386-392. [Abstract]